How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

When did Idera Pharmaceuticals' stock split?

Idera Pharmaceuticals's stock split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly minted shares were issued to shareholders after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com . Vincent Milano has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Idera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS) , BioCryst Pharmaceuticals (BCRX) , Sorrento Therapeutics (SRNE) , Novavax (NVAX) , Dynavax Technologies (DVAX) , Proteostasis Therapeutics (PTI) , Geron (GERN) , Rigel Pharmaceuticals (RIGL) , Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL) .

NASDAQ:IDRA

Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free IDRA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.17
▼
$7.23
52-Week Range: N/A

Volume: 21,870 shs
Average Volume: 464,030 shs
Market Capitalization: $450.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Idera Pharmaceuticals alerts:

Ad Altimetry

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

About Idera Pharmaceuticals Stock (NASDAQ:IDRA)

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Ad Altimetry

I’m officially sounding the alarm.

Just click here to watch my full uncensored interview.

IDRA Stock News Headlines

April 11, 2024 | fool.com

Ekso Bionics (NASDAQ: EKSO)

November 15, 2023 | forbes.com

Kiniksa Pharmaceuticals

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

August 9, 2023 | investing.com

Nabriva Therapeutics AG (NBRVF)

April 26, 2023 | npr.org

Marginalia

March 17, 2023 | washingtonpost.com

A mysterious rift propels the story in ‘Take What You Need’

January 18, 2023 | finanznachrichten.de

Idera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

January 17, 2023 | finance.yahoo.com

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

January 10, 2023 | msn.com

Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

January 4, 2023 | thestreet.com

Idera (IDRA) Stock Soars on GlaxoSmithKline Partnership

November 18, 2022 | finanznachrichten.de

Idera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 14, 2022 | finance.yahoo.com

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

September 29, 2022 | finance.yahoo.com

Idera Pharma Acquires Rare Disease Player, Names New CEO

September 28, 2022 | marketwatch.com

Idera Pharma Shares Rise Nearly 18% After Aceragen Acquisition

September 28, 2022 | finance.yahoo.com

Idera Pharmaceuticals Acquires Aceragen

September 27, 2022 | benzinga.com

Idera Pharmaceuticals Stock (NASDAQ:IDRA), Dividends

August 9, 2022 | finance.yahoo.com

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

May 17, 2022 | seekingalpha.com

Idera halts melanoma trial for cancer candidate after early positive results

May 17, 2022 | finance.yahoo.com

Why Are Idera Pharmaceuticals Shares Soaring Today

May 17, 2022 | finance.yahoo.com

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

May 5, 2022 | finance.yahoo.com

Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

March 31, 2022 | finance.yahoo.com

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

December 15, 2021 | msn.com

Idera Shares Fall After Early Tilsotolimod Data, Seeks Collaborating Partners For TLR9 Agonist

December 14, 2021 | finance.yahoo.com

Idera Pharmaceuticals Announces Tilsotolimod Updates

December 8, 2021 | chron.com

5 Penny Stocks To Buy According To Analysts & Targets Up To 341%

November 8, 2021 | finance.yahoo.com

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

See More Headlines

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IDRA
CUSIP: N/A
CIK: 861838
Web: www.iderapharma.com
Phone: (484) 348-1600
Fax: 617-679-5592
Employees: 32
Year Founded: 1989

Profitability

EPS (Most Recent Fiscal Year): ($0.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $98.09 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -68.74%
Return on Assets: -34.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.56
Quick Ratio: 1.56

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: 0.29
Book Value: $0.56 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 62,355,000
Free Float: 59,206,000
Market Cap: $450.52 million
Optionable: Optionable
Beta: 1.25

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. John J. Kirby CPA (Age 50)
Chief Financial Officer
Comp: $477.41k
Mr. Bryant David Lim (Age 51)
Chief Bus. Officer & Gen. Counsel
Comp: $480.96k
Mr. John C. Taylor (Age 52)
CEO & Director
Mr. Daniel Salain (Age 55)
Chief Operating Officer
Mr. Andy Jordan (Age 75)
Chief Strategy Officer
Dr. Carl Kraus M.D. (Age 53)
Chief Medical Officer
Dr. Shah Rahimian M.D.
Ph.D., Medical Director & Global Clinical Lead for Oncology
Dr. Joanna Caroline Horobin Ch.B (Age 67)
M.B., Advisor
Dr. Sudhir Agrawal D.Phil. (Age 68)
F.R.S.C., Scientific Advisor
Mr. Louis J. Arcudi III (Age 61)
M.B.A., MBA, Adviser

Key Competitors

View All Competitors

IDRA Stock Analysis - Frequently Asked Questions

How were Idera Pharmaceuticals' earnings last quarter?: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.
When did Idera Pharmaceuticals' stock split?: Idera Pharmaceuticals's stock split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly minted shares were issued to shareholders after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.
What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?: 7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees.
What other stocks do shareholders of Idera Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI), Geron (GERN), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL).

This page (NASDAQ:IDRA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis

About Idera Pharmaceuticals Stock (NASDAQ:IDRA)

IDRA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

IDRA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info